遗传因素而非原始细胞减少决定BCR-ABL阴性MPN急变期异基因HCT结局
基于CIBMTR数据库177例BCR-ABL阴性MPN急变期患者,95例(54%)接受49基因靶向测序。5年OS、累积复发率、非复发死亡率分别为18%、61%、25%。多因素分析显示不良核型与较差OS相关(HR 1.71),TP53突变(23%)与较差OS(HR 1.99)和更高复发(HR 2.59)相关;移植时PB/BM原始细胞<5%与活动性白血病患者结局无差异。
要点
- 不良核型与较差OS相关(HR 1.71;95%CI 1.21-2.41),因复发增加(HR 1.93;95%CI 1.32-2.82)。
- TP53突变(23%)是唯一与结局相关的基因改变,与较差OS(HR 1.99)和更高复发(HR 2.59)相关。
- 移植时PB/BM原始细胞<5%与活动性白血病患者结局无差异,常规HCT对TP53突变者无显著获益。
核心结论
- 遗传因素(核型异常和TP53突变状态)而非细胞减灭程度预测MPN-BP患者HCT结局。
- TP53突变的MPN-BP患者接受常规HCT未观察到有意义的获益。
研究设计与样本
- 回顾性队列研究,使用国际血液和骨髓移植研究中心(CIBMTR)数据库。
- 纳入177例BCR-ABL阴性MPN急变期接受HCT的患者,其中95例(54%)有足够DNA进行49个血液恶性肿瘤相关基因的靶向下一代测序。
主要发现
- 5年总生存率18%,累积复发率61%,非复发死亡率25%。
- 多因素模型中,不良核型与较差OS相关(HR 1.71;95%CI 1.21-2.41),因复发增加(HR 1.93;95%CI 1.32-2.82)。
- 使用动员外周血移植与更好OS相关(HR 0.60;95%CI 0.38-0.96)。
- PB/BM原始细胞<5%与活动性白血病患者HCT结局无差异,两组基因突变谱、突变数量、变异等位基因频率无差异。
- 95例分子数据患者中,TP53突变占23%,是唯一与结局相关的基因改变;TP53突变者OS较差(HR 1.99;95%CI 1.14-3.49),复发发生率更高(HR 2.59;95%CI 1.41-4.74)。
临床怎么用
- MPN-BP患者HCT前应评估核型和TP53突变状态以进行风险分层。
- TP53突变患者常规HCT获益有限,需考虑其他治疗策略。
- 移植时原始细胞水平不应作为排除HCT的唯一依据。
局限性
- 仅54%患者有足够DNA进行分子检测,可能存在选择偏倚。
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a limited understanding of the clinical and molecular factors associated with outcomes of hematopoietic cell transplantation (HCT) in patients with BCR-ABL-negative myeloproliferative neoplasms in blast phase (MPN-BP). Using the Center for International Blood and Marrow Transplant Research database, we evaluated HCT outcomes in 177 patients with MPN-BP. Ninety-five (54%) had sufficient DNA for targeted next-generation sequencing of 49 genes clinically relevant in hematologic malignancies. At 5 years, overall survival (OS), cumulative incidence of relapse, and nonrelapse mortality of the study cohort was 18%, 61%, and 25%, respectively. In a multivariable model, poor-risk cytogenetics was associated with inferior OS (hazard ratio [HR], 1.71; 95% CI, 1.21-2.41) due to increased relapse (HR, 1.93; 95% CI, 1.32-2.82). Transplants using mobilized peripheral blood (PB) were associated with better OS (HR, 0.60; 95% CI, 0.38-0.96). No difference in outcomes was observed in patients undergoing HCT with PB/BM blasts <5% vs those with active leukemia. Among the 95 patients with molecular data, mutation of TP53, present in 23%, was the only genetic alteration associated with outcomes. In a multivariate model, TP53-mutant patients had inferior OS (HR, 1.99; 95% CI, 1.14-3.49) and increased incidence of relapse (HR, 2.59; 95% CI, 1.41-4.74). There were no differences in the spectrum of gene mutations, number of mutations, or variant allele frequency between patients undergoing HCT with PB/BM blasts <5% vs those with active leukemia. Genetic factors, namely cytogenetic alterations and TP53 mutation status, rather than degree of cytoreduction predict outcomes of HCT in MPN-BP. No meaningful benefit of conventional HCT was observed in patients with MPN-BP and mutated TP53.
引用
- Gupta V, Kennedy JA, Capo-Chichi JM, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. Blood Adv. 2020. PMID: 33170935. doi:10.1182/bloodadvances.2020002727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。